On December 4, 2025 LabGenius Therapeutics ("LabGenius"), a drug discovery company combining machine learning (ML) and high-throughput experimentation to optimise potential therapeutic antibodies, reported a second collaboration with Sanofi. This collaboration combines LabGenius’ AI/ML-driven antibody design capabilities with Sanofi’s expertise in the development of therapeutic NANOBODY molecules to co-optimise proteins for therapeutically valuable properties. Following the success of their first collaboration, LabGenius will apply the EVA platform to optimise NANOBODY molecules for multiple new targets in the area of inflammation.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

"We are truly excited about this new collaboration with Sanofi," said LabGenius’ CSO, Dr. Angus Sinclair. "This partnership serves as strong validation of our platform’s unique ability to tackle complex antibody co-optimisation challenges across a wide range of therapeutic targets, ultimately driving better outcomes for patients."

(Press release, LabGenius Therapeutics, DEC 4, 2025, View Source [SID1234661122])